The Cooper Companies, IncCooper lowered its adjusted EPS and revenue forecasts and disappointed investors by retaining CooperSurgical instead of selling it, though it raised its buyback authorization.

The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected demand for contact lenses weighed on its CooperVision business. The company now expects adjusted earnings of $4.51 to $4.55 per share, down from its previous forecast of $4.58 to $4.66, while revenue guidance was reduced to $4.23 to $4.25 billion from $4.29 to $4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate, although adjusted EPS of $1.15 beat expectations. The weakness was concentrated in CooperVision, where revenue fell to $717 million, and Cooper said a reduction in U.S. channel inventory hurt results and is expected to continue affecting the fourth quarter. The company also completed its strategic review and decided to retain CooperSurgical rather than sell the business, disappointing investors, while increasing its share-repurchase authorization from $2 billion to $3 billion.
The Cooper Companies, IncCooper lowered its adjusted EPS and revenue forecasts and disappointed investors by retaining CooperSurgical instead of selling it, though it raised its buyback authorization.
Enbridge Inc
TotalEnergies SE